{"id":6412,"date":"2017-05-02T16:36:09","date_gmt":"2017-05-02T16:36:09","guid":{"rendered":"https:\/\/www.olartemoure.com\/web\/?p=6412\/"},"modified":"2017-05-02T16:36:09","modified_gmt":"2017-05-02T16:36:09","slug":"om-weekly-digest-10-02-2017","status":"publish","type":"post","link":"https:\/\/olartemoure.com\/en\/om-weekly-digest-10-02-2017\/","title":{"rendered":"OM Weekly Digest (10-02-2017)"},"content":{"rendered":"<p><a href=\"http:\/\/www.olartemoure.com\/wp-content\/uploads\/2016\/10\/OM-WD-English-title.jpg\"><img decoding=\"async\" class=\"aligncenter wp-image-5130 size-full\" src=\"http:\/\/www.olartemoure.com\/wp-content\/uploads\/2016\/10\/OM-WD-English-title.jpg\" width=\"800\" height=\"108\" \/><\/a><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #ffffff;\">.<\/span><\/p>\n<h3 style=\"text-align: center;\"><span style=\"text-decoration: underline;\"><strong>COLOMBIA\u00a0| Patents, Regulatory\u00a0|\u00a0Inclusion of Glivec<\/strong><\/span><span style=\"text-decoration: underline;\"><strong>\u00ae under Colombian price control regime for pharmaceuticals affected by Declarations of Public Interest entered into force<\/strong><\/span><\/h3>\n<p><span style=\"color: #ffffff;\">.<\/span><\/p>\n<p style=\"text-align: justify;\">On 3 February 2017, entered into force <span style=\"text-decoration: underline;\"><a href=\"https:\/\/www.minsalud.gov.co\/sites\/rid\/Lists\/BibliotecaDigital\/RIDE\/DE\/DIJ\/circular-cnm-04-2016.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Resolution (Circular) 4 of 2016<\/a><\/span>, through which the National Pharmaceutical Price Commission (NPPC) included Glivec\u00ae -of Novartis- to the direct control of prices established in <span style=\"text-decoration: underline;\"><a href=\"https:\/\/www.minsalud.gov.co\/sites\/rid\/Lists\/BibliotecaDigital\/RIDE\/VS\/MET\/circular-03-de-2016.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Resolution (Circular) 3 of 2016<\/a><\/span> by the Colombian Ministry of Health, for medicines affected by Declarations of Public Interest (DPI)<\/p>\n<p style=\"text-align: justify;\">The methodology established in Circular 3\/2016 is highly controversial, by stipulating that the medicines subject to price control must have as maximum sales value, the lowest price of all competitors in the countries of reference (using generic imatinib prices).<\/p>\n<h3 style=\"text-align: center;\"><span style=\"color: #ffffff;\">.\u00a0<\/span><\/h3>\n<div style=\"text-align: justify;\">\n<h3 style=\"text-align: center;\"><span style=\"text-decoration: underline;\"><strong>COLOMBIA\u00a0| Intelectual Property\u00a0| Modification to the Colombian foreign investment regime has implications in Intellectual Property<\/strong><\/span><\/h3>\n<\/div>\n<p style=\"text-align: justify;\">On 26 January 2017, the Colombian Government issued <span style=\"text-decoration: underline;\"><a href=\"http:\/\/es.presidencia.gov.co\/normativa\/normativa\/DECRETO%20119%20DEL%2026%20ENERO%20DE%202017.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Decree 119\/2017<\/a><\/span>, which modifies the foreign capital investment regime in that country (contained in <span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.banrep.gov.co\/sites\/default\/files\/reglamentacion\/archivos\/d1068.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Decree 1068\/2015<\/a><\/span>)<\/p>\n<p style=\"text-align: justify;\">The new Decree considers that all\u00a0direct investments of &#8220;non-Residents&#8221; (natural and legal\u00a0persons that do not have their man domicile in Colombia, or natural persons that do not remain in the country more than 183 calendar days a year) made on intangible assets acquired for the purpose of being used to obtain an economic benefit in the country (as royalties), shall be understood as foreign capital investments.<\/p>\n<p style=\"text-align: justify;\">As a consequence of the above, <span style=\"text-decoration: underline;\"><a href=\"https:\/\/translate.google.com\/translate?hl=es-419&amp;sl=es&amp;tl=en&amp;u=http%3A%2F%2Fwww.banrep.gov.co%2Fes%2Fnode%2F34887\" target=\"_blank\" rel=\"noopener noreferrer\">any non-resident who acquires trademarks, patents, copyright protected works, etc., must be registered before the Colombian\u00a0Central Bank (Banco de la Rep\u00fablica) to expatriate royalties<\/a><\/span>. \u00a0These obligations only apply if royalties are paid.<\/p>\n<h3 style=\"text-align: center;\"><span style=\"text-decoration: underline;\"><strong>USA\u00a0| Copyright\u00a0|\u00a0USA: Copyright Alert System ends<\/strong><\/span><\/h3>\n<h3><strong><em>\u00a0<\/em><\/strong><\/h3>\n<div style=\"text-align: justify;\">On January 2017, US Internet Services Providers (ISPs) and Copyright titleholders subscribed to the <span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.copyrightinformation.org\/the-copyright-alert-system\/what-is-a-copyright-alert\/\" target=\"_blank\" rel=\"noopener noreferrer\">Copyright Alert System<\/a><\/span>\u00a0stopped its application (implemented by themselves in 2013 through the <span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.copyrightinformation.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">Center for Copyright Information<\/a><\/span> -CCI-).<\/div>\n<div style=\"text-align: justify;\"><span style=\"color: #ffffff;\">.<\/span><\/div>\n<div style=\"text-align: justify;\">The system was based on six strikes for users accessing to protected content in an unauthorized manner, and included &#8220;mitigation measures&#8221; as temporary slow-down of internet access speed, or temporary redirection to an educative page in copyright.<\/div>\n<div style=\"text-align: justify;\"><span style=\"color: #ffffff;\">.<\/span><\/div>\n<div>\n<p style=\"text-align: justify;\"><span style=\"text-decoration: underline;\"><a href=\"https:\/\/translate.google.com\/translate?hl=es-419&amp;sl=en&amp;tl=es&amp;u=http%3A%2F%2Fwww.copyrightinformation.org%2Fstatement%2Fstatement-on-the-copyright-alert-system%2F\" target=\"_blank\" rel=\"noopener noreferrer\">The oficial statement about the conclusion of the Copyright Alert System does not indicate reasons for its end<\/a><\/span>. \u00a0However, it is believed that this could be because the system was only capable of monitor content shared in peer-to-peer networks, excluding other means of distribution (as streaming).<\/p>\n<\/div>\n<div style=\"text-align: justify;\"><span style=\"color: #ffffff;\">\u00a0.<\/span><\/div>\n<div style=\"text-align: justify;\">\n<h3 style=\"text-align: center;\"><span style=\"text-decoration: underline;\"><strong>COLOMBIA\u00a0| Intellectual Property, Copyright, Regulatory | New Minor Offences Law entered into force in Colombia: provisions related to intellectual property and regulatory<\/strong><\/span><\/h3>\n<\/div>\n<p style=\"text-align: justify;\">Approved by <span style=\"text-decoration: underline;\"><a href=\"https:\/\/translate.google.com\/translate?hl=es-419&amp;sl=es&amp;tl=en&amp;u=http%3A%2F%2Fwww.imprenta.gov.co%2Fgacetap%2Fgaceta.mostrar_documento%3Fp_tipo%3D21%26p_numero%3D1801%26p_consec%3D45806\" target=\"_blank\" rel=\"noopener noreferrer\">Law 1801 of 2016<\/a><\/span>, on 30 January 2017 started the application of a new Minor Offences Law in Colombia, replacing the previous one (issued on 1970).<\/p>\n<p style=\"text-align: justify;\">In intellectual property matters, the new regulation reiterates and\/or includes sanctions in the following areas:<\/p>\n<ul>\n<li style=\"text-align: justify;\">If payment of royalties in copyright to holders of protected content is not met. \u00a0As an example, in\u00a0the case of economic activities in establishments where musical copyrighted works are publicly executed, it is required as a mandatory requirement for the development of the economic activity, the presentation of up-to-date proof of payment in favor of its titleholders or representants\u00a0(such as Collective Management Societies).<\/li>\n<\/ul>\n<p><span style=\"color: #ffffff;\">.<\/span><\/p>\n<p>In regulatory law, there will be sanctions:<\/p>\n<ul>\n<li style=\"text-align: justify;\">If\u00a0behaviors that threaten public health are committed (as the storage and commercialization of foods that do no comply with the sanitary regulations of the Colombian Regulatory Authority)<\/li>\n<\/ul>\n<p><span style=\"color: #ffffff;\">.<\/span><\/p>\n<p>Failure to comply with any of the provisions, implies the temporary or definitive suspension of the commercial activity, as well as fines depending on the severity of the behavior.<\/p>\n<div style=\"text-align: justify;\"><span style=\"color: #ffffff;\">\u00a0.<\/span><\/div>\n<div style=\"text-align: justify;\">\n<h3 style=\"text-align: center;\"><span style=\"text-decoration: underline;\"><strong>COLOMBIA\u00a0| Intellectual Property\u00a0| Colombian Patent and Trademark Office updates its internal administrative procedure in accordance with procedural\u00a0laws issued in the last 5 years<\/strong><\/span><\/h3>\n<\/div>\n<p style=\"text-align: justify;\">On 30 January 2017\u00a0-and by means of <span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.sic.gov.co\/sites\/default\/files\/normatividad\/Resolucion_2356_2017.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Regulation 2356\/2017<\/a><\/span>&#8211; the Superintendence of Industry and Commerce (SIC) updated its principal regulation (<span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.sic.gov.co\/titulos-circular-unica\" target=\"_blank\" rel=\"noopener noreferrer\">Circular \u00danica<\/a><\/span>) in accordance with the procedural laws issued in Colombia during the last 5 years.<\/p>\n<p style=\"text-align: justify;\">Its main novelty is in\u00a0its update in accordance with the provisions of <span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.alcaldiabogota.gov.co\/sisjur\/normas\/Norma1.jsp?i=62152\" target=\"_blank\" rel=\"noopener noreferrer\">Law 1755 of 2015<\/a><\/span>, which regulates the &#8220;Petition Right&#8221; (Derecho de Petici\u00f3n in Spanish) procedure before public entities in Colombia.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>. COLOMBIA\u00a0| Patents, Regulatory\u00a0|\u00a0Inclusion of Glivec\u00ae under Colombian price control regime for pharmaceuticals affected by Declarations of Public Interest entered into force . On 3 February 2017, entered into force Resolution (Circular) 4 of 2016, through which the National Pharmaceutical Price Commission (NPPC) included Glivec\u00ae -of Novartis- to the direct control of prices established in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6260,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[59],"tags":[],"class_list":["post-6412","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-newsletter-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.4 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>OM Weekly Digest (10-02-2017) - OlarteMoure | Intellectual Property<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/olartemoure.com\/en\/om-weekly-digest-10-02-2017\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OM Weekly Digest (10-02-2017)\" \/>\n<meta property=\"og:description\" content=\". COLOMBIA\u00a0| Patents, Regulatory\u00a0|\u00a0Inclusion of Glivec\u00ae under Colombian price control regime for pharmaceuticals affected by Declarations of Public Interest entered into force . On 3 February 2017, entered into force Resolution (Circular) 4 of 2016, through which the National Pharmaceutical Price Commission (NPPC) included Glivec\u00ae -of Novartis- to the direct control of prices established in [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/olartemoure.com\/en\/om-weekly-digest-10-02-2017\/\" \/>\n<meta property=\"og:site_name\" content=\"OlarteMoure | Intellectual Property\" \/>\n<meta property=\"article:published_time\" content=\"2017-05-02T16:36:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Imagen-eng-03.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"842\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-10-02-2017\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-10-02-2017\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/d3c1a99aa6e1d8fc8bb6a5c4dee16807\"},\"headline\":\"OM Weekly Digest (10-02-2017)\",\"datePublished\":\"2017-05-02T16:36:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-10-02-2017\\\/\"},\"wordCount\":651,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-10-02-2017\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2016\\\/11\\\/Imagen-eng-03.jpg\",\"articleSection\":[\"Newsletter\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-10-02-2017\\\/\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-10-02-2017\\\/\",\"name\":\"OM Weekly Digest (10-02-2017) - OlarteMoure | Intellectual Property\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-10-02-2017\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-10-02-2017\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2016\\\/11\\\/Imagen-eng-03.jpg\",\"datePublished\":\"2017-05-02T16:36:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/d3c1a99aa6e1d8fc8bb6a5c4dee16807\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-10-02-2017\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-10-02-2017\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-10-02-2017\\\/#primaryimage\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2016\\\/11\\\/Imagen-eng-03.jpg\",\"contentUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2016\\\/11\\\/Imagen-eng-03.jpg\",\"width\":\"842\",\"height\":\"482\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/om-weekly-digest-10-02-2017\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OM Weekly Digest (10-02-2017)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#website\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/\",\"name\":\"OlarteMoure | Intellectual Property\",\"description\":\"Firma especializada en Propiedad Intelectual\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/olartemoure.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/d3c1a99aa6e1d8fc8bb6a5c4dee16807\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"OM Weekly Digest (10-02-2017) - OlarteMoure | Intellectual Property","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/olartemoure.com\/en\/om-weekly-digest-10-02-2017\/","og_locale":"en_US","og_type":"article","og_title":"OM Weekly Digest (10-02-2017)","og_description":". COLOMBIA\u00a0| Patents, Regulatory\u00a0|\u00a0Inclusion of Glivec\u00ae under Colombian price control regime for pharmaceuticals affected by Declarations of Public Interest entered into force . On 3 February 2017, entered into force Resolution (Circular) 4 of 2016, through which the National Pharmaceutical Price Commission (NPPC) included Glivec\u00ae -of Novartis- to the direct control of prices established in [&hellip;]","og_url":"https:\/\/olartemoure.com\/en\/om-weekly-digest-10-02-2017\/","og_site_name":"OlarteMoure | Intellectual Property","article_published_time":"2017-05-02T16:36:09+00:00","og_image":[{"width":842,"height":482,"url":"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Imagen-eng-03.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-10-02-2017\/#article","isPartOf":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-10-02-2017\/"},"author":{"name":"admin","@id":"https:\/\/olartemoure.com\/#\/schema\/person\/d3c1a99aa6e1d8fc8bb6a5c4dee16807"},"headline":"OM Weekly Digest (10-02-2017)","datePublished":"2017-05-02T16:36:09+00:00","mainEntityOfPage":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-10-02-2017\/"},"wordCount":651,"commentCount":0,"image":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-10-02-2017\/#primaryimage"},"thumbnailUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Imagen-eng-03.jpg","articleSection":["Newsletter"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-10-02-2017\/","url":"https:\/\/olartemoure.com\/en\/om-weekly-digest-10-02-2017\/","name":"OM Weekly Digest (10-02-2017) - OlarteMoure | Intellectual Property","isPartOf":{"@id":"https:\/\/olartemoure.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-10-02-2017\/#primaryimage"},"image":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-10-02-2017\/#primaryimage"},"thumbnailUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Imagen-eng-03.jpg","datePublished":"2017-05-02T16:36:09+00:00","author":{"@id":"https:\/\/olartemoure.com\/#\/schema\/person\/d3c1a99aa6e1d8fc8bb6a5c4dee16807"},"breadcrumb":{"@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-10-02-2017\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/olartemoure.com\/en\/om-weekly-digest-10-02-2017\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-10-02-2017\/#primaryimage","url":"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Imagen-eng-03.jpg","contentUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2016\/11\/Imagen-eng-03.jpg","width":"842","height":"482"},{"@type":"BreadcrumbList","@id":"https:\/\/olartemoure.com\/en\/om-weekly-digest-10-02-2017\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/olartemoure.com\/en\/"},{"@type":"ListItem","position":2,"name":"OM Weekly Digest (10-02-2017)"}]},{"@type":"WebSite","@id":"https:\/\/olartemoure.com\/#website","url":"https:\/\/olartemoure.com\/","name":"OlarteMoure | Intellectual Property","description":"Firma especializada en Propiedad Intelectual","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/olartemoure.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/olartemoure.com\/#\/schema\/person\/d3c1a99aa6e1d8fc8bb6a5c4dee16807","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/dc39656c8e7d8a5a4ca66eb97abd4b095991d687cfd38af1e37bac8f9cb122b7?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/olartemoure.com\/en\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts\/6412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/comments?post=6412"}],"version-history":[{"count":0,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts\/6412\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/media\/6260"}],"wp:attachment":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/media?parent=6412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/categories?post=6412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/tags?post=6412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}